On January 19, 2024, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share. Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses. The closing of the offering occurred on January 23, 2024. Wilson Sonsini Goodrich & Rosati represented Edgewise Therapeutics on the transaction.

Edgewise intends to use the net proceeds from the offering to support the potential U.S. commercial launch of EDG-5506 in patients with Becker muscular dystrophy, completion of a Phase 3 trial with EDG-5506 in Duchenne, completion of Phase 2 trials of EDG-7500 in patients with obstructive and non-obstructive hypertrophic cardiomyopathy and the advancement of Edgewise’s ongoing research and development programs, and for working capital and general corporate purposes.

The Wilson Sonsini team that represented Edgewise Therapeutics on the transaction includes:

Corporate
Tony Jeffries
Jennifer Knapp
Rachel Nagashima
James Babikian
Zack Lenox
Michael Anthony

Patents and Innovations
Julia Minitti
Grant Margulieux

For more information, please see Edgewise Therapeutics' news release.